Data gathered: February 1
AI Stock Analysis - Arrowhead Pharmaceuticals (ARWR)
Analysis generated November 26, 2024. Powered by Chat GPT.
Arrowhead Pharmaceuticals, a biopharmaceutical company, is involved in the development of RNA interference (RNAi) medicines. The company focuses on therapeutics that cure intractable diseases by silencing the genes that cause them. With a strong pipeline of drug candidates targeting diseases such as hepatitis B, cystic fibrosis, and cardiovascular diseases, Arrowhead leverages its proprietary technology to tackle conditions with unmet medical needs.
Stock Alerts - Arrowhead Pharmaceuticals (ARWR)
 |
Arrowhead Pharmaceuticals | January 28 Insider Alert: OLUKOTUN ADEOYE Y is selling shares |
|
Arrowhead Pharmaceuticals | January 24 Price is down by -5.3% in the last 24h. |
|
Arrowhead Pharmaceuticals | January 23 Price is up by 5.9% in the last 24h. |
|
Arrowhead Pharmaceuticals | January 15 Price is up by 5% in the last 24h. |
Alternative Data for Arrowhead Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 20 | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 27,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | 18 | Sign up | Sign up | Sign up |
| Patents | 93 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,817 | Sign up | Sign up | Sign up |
| Twitter Followers | 3,627 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 73 | Sign up | Sign up | Sign up |
| Linkedin Employees | 551 | Sign up | Sign up | Sign up |
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
| Price | $19.88 |
| Target Price | Sign up |
| Volume | 1,300,000 |
| Market Cap | $2.49B |
| Year Range | $17.7 - $29.54 |
| Dividend Yield | 0% |
| Analyst Rating | 60% buy |
| Earnings Date | February 10 '25 |
| Industry | Biotechnology |
In the news
 |
Arrowhead Pharmaceuticals (ARWR) to Release Earnings on TuesdayJanuary 28 - ETF Daily News |
|
HC Wainwright Has Negative Outlook for ARWR FY2026 EarningsJanuary 27 - ETF Daily News |
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) dropped from S&P 400 - BiotechnologyJanuary 26 - Finnhub |
|
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) dropped from S&P 400January 26 - Finnhub |
|
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) added to S&P 600January 26 - Finnhub |
|
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) dropped from S&P 400 Health CareJanuary 26 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 31M | -32M | -171M | -157M | -1.370 |
| Q2 '24 | 0 | 24M | -24M | -171M | -171M | -1.380 |
| Q1 '24 | 0 | 25M | -33M | -125M | -114M | -1.020 |
| Q4 '23 | 3.6M | 28M | -30M | -133M | -127M | -1.240 |
| Q3 '23 | 11M | 28M | -18M | -110M | -99M | -1.020 |
Insider Transactions View All
| OLUKOTUN ADEOYE Y filed to sell 35,781 shares at $21. January 27 '25 |
| Myszkowski Kenneth Allen filed to sell 465,433 shares at $19.7. January 7 '25 |
| O'Brien Patrick filed to sell 527,201 shares at $19.7. January 7 '25 |
| Myszkowski Kenneth Allen filed to sell 455,433 shares at $19.7. January 7 '25 |
| Myszkowski Kenneth Allen filed to sell 473,433 shares at $20.1. January 7 '25 |
Similar companies
Read more about Arrowhead Pharmaceuticals (ARWR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Arrowhead Pharmaceuticals?
The Market Cap of Arrowhead Pharmaceuticals is $2.49B.
When does Arrowhead Pharmaceuticals report earnings?
Arrowhead Pharmaceuticals will report its next earnings on February 10 '25.
What is the current stock price of Arrowhead Pharmaceuticals?
Currently, the price of one share of Arrowhead Pharmaceuticals stock is $19.88.
How can I analyze the ARWR stock price chart for investment decisions?
The ARWR stock price chart above provides a comprehensive visual representation of Arrowhead Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arrowhead Pharmaceuticals shares. Our platform offers an up-to-date ARWR stock price chart, along with technical data analysis and alternative data insights.
Does ARWR offer dividends to its shareholders?
As of our latest update, Arrowhead Pharmaceuticals (ARWR) does not offer dividends to its shareholders. Investors interested in Arrowhead Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Arrowhead Pharmaceuticals?
Some of the similar stocks of Arrowhead Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.